The estimated Net Worth of Samuel Backenroth is at least $557 ezer dollars as of 31 March 2023. Mr Backenroth owns over 525,000 units of NeuBase Therapeutics stock worth over $198,450 and over the last 11 years he sold NBSE stock worth over $0. In addition, he makes $358,524 as CFO és Treasurer & Sec. at NeuBase Therapeutics.
Mr has made over 6 trades of the NeuBase Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 525,000 units of NBSE stock worth $198,450 on 31 March 2023.
The largest trade he's ever made was exercising 525,000 units of NeuBase Therapeutics stock on 31 March 2023 worth over $198,450. On average, Mr trades about 46,454 units every 229 days since 2014. As of 31 March 2023 he still owns at least 525,000 units of NeuBase Therapeutics stock.
You can see the complete history of Mr Backenroth stock trades at the bottom of the page.
Samuel Backenroth is the CFO, Treasurer & Sec. at NeuBase Therapeutics.
As the CFO és Treasurer & Sec. of NeuBase Therapeutics, the total compensation of Mr Backenroth at NeuBase Therapeutics is $358,524. There are 8 executives at NeuBase Therapeutics getting paid more, with Dietrich Stephan having the highest compensation of $3,677,280.
Mr Backenroth is 36, he's been the CFO és Treasurer & Sec. of NeuBase Therapeutics since . There are 9 older and 1 younger executives at NeuBase Therapeutics. The oldest executive at NeuBase Therapeutics, Inc. is Franklyn Prendergast, 75, who is the Independent Director.
Samuel's mailing address filed with the SEC is C/O VASCULAR BIOGENICS LTD., 8 HASATAT ST, MODI'IN,, L3, 7178106.
Over the last 5 years, insiders at NeuBase Therapeutics have traded over $713,184 worth of NeuBase Therapeutics stock and bought 177,514 units worth $548,788 . The most active insiders traders include Dov A Md Goldstein, Dietrich A Stephan és Samuel Backenroth. On average, NeuBase Therapeutics executives and independent directors trade stock every 56 days with the average trade being worth of $37,929. The most recent stock trade was executed by Corp Symetryx on 14 September 2023, trading 282,445 units of NBSE stock currently worth $375,652.
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
NeuBase Therapeutics executives and other stock owners filed with the SEC include: